Optimizing tylosin dosage for co-infection of Actinobacillus pleuropneumoniae and Pasteurella multocida in pigs using pharmacokinetic/pharmacodynamic modeling

• Published in: Frontiers in pharmacology Vol. 14; p. 1258403
• Main Authors: Lee, Eon-Bee, Abbas, Muhammad Aleem, Park, Jonghyun, Tassew, Dereje D., Park, Seung-Chun
• Format: Journal Article
• Language: English
• Published: Frontiers Media S.A 22.09.2023
• Subjects: Actinobacillus pleuropneumoniae; dosage optimization; Monte Carlo simulation; Pasteurella multocida; pharmacokinetic/pharmacodynamic modeling; Pharmacology
• ISSN: 1663-9812; 1663-9812
• DOI: 10.3389/fphar.2023.1258403

Formulating a therapeutic strategy that can effectively combat concurrent infections of Actinobacillus pleuropneumoniae ( A. pleuropneumoniae ) and Pasteurella multocida ( P. multocida ) can be challenging. This study aimed to 1) establish minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC), time kill curve, and post-antibiotic effect (PAE) of tylosin against A. pleuropneumoniae and P. multocida pig isolates and employ the MIC data for the development of epidemiological cutoff (ECOFF) values; 2) estimate the pharmacokinetics (PKs) of tylosin following its intramuscular (IM) administration (20 mg/kg) in healthy and infected pigs; and 3) establish a PK–pharmacodynamic (PD) integrated model and predict optimal dosing regimens and PK/PD cutoff values for tylosin in healthy and infected pigs. The MIC of tylosin against both 89 and 363 isolates of A. pleuropneumoniae and P. multocida strains spread widely, ranging from 1 to 256 μg/mL and from 0.5 to 128 μg/mL, respectively. According to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) ECOFFinder analysis ECOFF value (≤64 µg/mL), 97.75% (87 strains) of the A. pleuropnumoniae isolates were wild-type, whereas with the same ECOFF value (≤64 µg/mL), 99.72% (363 strains) of the P. multicoda isolates were considered wild-type to tylosin. Area under the concentration time curve (AUC), T 1/2 , and C max values were significantly greater in healthy pigs than those in infected pigs (13.33 h × μg/mL, 1.99 h, and 5.79 μg/mL vs. 10.46 h × μg/mL, 1.83 h, and 3.59 μg/mL, respectively) ( p < 0.05). In healthy pigs, AUC 24 h /MIC values for the bacteriostatic activity were 0.98 and 1.10 h; for the bactericidal activity, AUC 24 h /MIC values were 1.97 and 1.99 h for A. pleuropneumoniae and P. multocida , respectively. In infected pigs, AUC 24 h /MIC values for the bacteriostatic activity were 1.03 and 1.12 h; for bactericidal activity, AUC 24 h /MIC values were 2.54 and 2.36 h for A. pleuropneumoniae and P. multocida , respectively. Monte Carlo simulation lead to a 2 μg/mL calculated PK/PD cutoff. Managing co-infections can present challenges, as it often demands the administration of multiple antibiotics to address diverse pathogens. However, using tylosin, which effectively targets both A. pleuropneumoniae and P. multocida in pigs, may enhance the control of bacterial burden. By employing an optimized dosage of 11.94–15.37 mg/kg and 25.17–27.79 mg/kg of tylosin can result in achieving bacteriostatic and bactericidal effects in 90% of co-infected pigs.